Trials / Completed
CompletedNCT03905291
Pharmacokinetic/Pharmacodynamic Characteristics and Safety/Tolerability of MT921 in Healthy Subjects
A Randomized, Double-blinded, Placebo-controlled, Single Center, Dose Escalation, Phase I Study to Evaluate the Pharmacokinetic/Pharmacodynamic Characteristics and Safety/Tolerability of MT921 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Medy-Tox · Industry
- Sex
- All
- Age
- 20 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
To determine the pharmacokinetic/pharmacodynamic characteristics and safety/tolerability of MT921 in Healthy Subjects
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MT921 | Formulated as an injectable solution |
| DRUG | Placebo | normal saline |
Timeline
- Start date
- 2018-07-31
- Primary completion
- 2018-12-26
- Completion
- 2018-12-26
- First posted
- 2019-04-05
- Last updated
- 2020-08-25
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03905291. Inclusion in this directory is not an endorsement.